原发性乳腺癌的辅助性间歇化学免疫疗法：一项具有免疫学随访的前瞻性研究。

Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up.

作者信息

Betzler M, Schreml W, Lang M, Lohrmann H P, Flad H D, Schlag P, Herfarth C, Heimpel H

出版信息

Recent Results Cancer Res. 1982;80:185-91. doi: 10.1007/978-3-642-81685-7_30.

Abstract

In an interdisciplinary prospective study 50 patients surgically treated for breast cancer were treated with six monthly courses of aggressive adjuvant chemotherapy (adriamycin and cyclophosphamide) and were randomized to receive either immunotherapy with levamisole or no additional therapy. Probability of disease-free survival for the whole group is 54.9% at 42 months. There was no noticeable difference in disease-free survival for either pre- and postmenopausal women or for patients treated with or without levamisole. The addition of levamisole had no effect on the depression of in vitro immunologic functions during chemotherapy.

摘要

在一项跨学科前瞻性研究中，50例接受乳腺癌手术治疗的患者接受了为期6个月的强化辅助化疗（阿霉素和环磷酰胺），并被随机分为接受左旋咪唑免疫治疗组或不接受额外治疗组。42个月时，整个组无病生存率为54.9%。绝经前和绝经后女性，以及接受或未接受左旋咪唑治疗的患者，其无病生存率均无明显差异。添加左旋咪唑对化疗期间体外免疫功能的抑制没有影响。